Aktieanalys

Vicore Pharma: VP03 Ready for the Clinic - Redeye

Redeye Publicerad: 23 Feb 2022 11:57

Redeye is encouraged to learn about the progress with Vicore’s VP03 program and the acceleration of the first compound, C106, into clinic (application due in Q2). The company has further developed its internal drug development capacity, with four additional A2TR agonistic compounds expected to be ready by the end of 2022. This indicates the beginning of a transition into a platform company with a broader clinical pipeline. Vicore will host an R&D day in March and update the market further - we look forward to get further information about the program.

Länk till analysen i sin helhet: https://www.redeye.se/research/834297/vicore-pharma-vp03-ready-for-the-clinic?utm_source=finwire&utm_medium=RSS

Nyheter om Vicore Pharma

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!